Revolution Medicines, Inc. RVMD
We take great care to ensure that the data presented and summarized in this overview for Revolution Medicines, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RVMD
View all-
Vanguard Group Inc Valley Forge, PA15.8MShares$749 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA14.3MShares$680 Million2.37% of portfolio
-
Black Rock Inc. New York, NY13.4MShares$637 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X010.6MShares$503 Million0.2% of portfolio
-
Wellington Management Group LLP Boston, MA10.3MShares$487 Million0.07% of portfolio
-
Baker Bros. Advisors LP New York, NY9.36MShares$445 Million3.49% of portfolio
-
Nextech Invest Ag7.6MShares$361 Million61.97% of portfolio
-
Nextech Invest, Ltd. Zurich, V87.6MShares$361 Million52.92% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY6.09MShares$289 Million10.46% of portfolio
-
Bvf Inc San Francisco, CA4.98MShares$237 Million7.2% of portfolio
Latest Institutional Activity in RVMD
Top Purchases
Top Sells
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Insider Transactions at RVMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 24
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,799
-3.44%
|
$79,156
$44.26 P/Share
|
|
Sep 16
2025
|
Lin Wei Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,160
-2.39%
|
$97,200
$45.82 P/Share
|
|
Sep 16
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,320
-2.05%
|
$104,400
$45.82 P/Share
|
|
Sep 16
2025
|
Jeff Cislini General Counsel |
SELL
Open market or private sale
|
Direct |
1,869
-3.46%
|
$84,105
$45.82 P/Share
|
|
Sep 16
2025
|
Margaret A Horn Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,775
-3.17%
|
$214,875
$45.82 P/Share
|
|
Sep 16
2025
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Direct |
13,411
-2.88%
|
$603,495
$45.82 P/Share
|
|
Sep 16
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
5,367
-1.85%
|
$241,515
$45.82 P/Share
|
|
Sep 15
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
25,000
-3.99%
|
$1,150,000
$46.42 P/Share
|
|
Sep 15
2025
|
Stephen Michael Kelsey |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+7.37%
|
$100,000
$4.73 P/Share
|
|
Sep 11
2025
|
Stephen Michael Kelsey |
SELL
Open market or private sale
|
Direct |
100,000
-13.76%
|
$4,400,000
$44.03 P/Share
|
|
Sep 11
2025
|
Stephen Michael Kelsey |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+20.43%
|
$400,000
$4.73 P/Share
|
|
Sep 03
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,238
-4.42%
|
$209,520
$40.17 P/Share
|
|
Sep 03
2025
|
Jack Anders Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,238
+2.18%
|
$52,380
$10.87 P/Share
|
|
Sep 02
2025
|
Jack Anders Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,762
-4.03%
|
$190,480
$40.02 P/Share
|
|
Sep 02
2025
|
Jack Anders Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,762
+1.99%
|
$14,286
$3.71 P/Share
|
|
Jun 30
2025
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
37,000
+7.36%
|
$0
$0.54 P/Share
|
|
Jun 26
2025
|
Alexis Borisy |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+0.13%
|
-
|
|
Jun 26
2025
|
Lorence H. Kim |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+4.12%
|
-
|
|
Jun 26
2025
|
Sushil Patel |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+11.98%
|
-
|
|
Jun 26
2025
|
Sandra Horning |
BUY
Grant, award, or other acquisition
|
Direct |
3,142
+3.15%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 246K shares |
|---|---|
| Open market or private purchase | 1.3M shares |
| Exercise of conversion of derivative security | 327K shares |
| Open market or private sale | 347K shares |
|---|---|
| Bona fide gift | 2.72K shares |
| Grant, award, or other acquisition | 20.8K shares |